Sign up USA
Proactive Investors - Run By Investors For Investors

Akers Biosciences surges after beefing up commercial team

The two recruits have skill sets that are highly relevant to Akers's commercial strategy
Akers Biosciences surges after beefing up commercial team
Akers develops and supplies rapid screening and testing products

Akers Biosciences (LON:AKR, NASDAQ:AKER), a developer of health information technologies, has strengthened its commercial team with two sales and marketing recruits.

Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.

Carrara has over 25 years' experience in the clinical diagnostics arena, particularly within sales, marketing and global operations. He joins Akers Bio from Quest Diagnostics where he was the senior director of Strategic Accounts, leading a team of directors responsible for developing and implementing strategic relationships within the acute care market.

Saporito has a track record of building and leading high-performance businesses in the medical device and clinical diagnostics arenas for two decades. Prior to joining Akers Bio, he held the role of strategic account executive with The Midmark Corporation, where he was responsible for driving new business through group purchasing organisations, integrated health systems and distribution.

“Their skill sets are highly relevant to our commercial strategy for growing product sales over the coming years and we are very excited to have them on board," said Raymond Akers, co-founder and executive chairman of the dual-listed medical screening and testing products developer.

Chief executive John Gormally said: "Having worked with both Douglas and Tony at Becton Dickinson, I have direct experience of their first class abilities to execute highly profitable sales strategies.

"Douglas will be instrumental in building an evidence-based outcome value proposition marketing strategy, particularly to support the growth of Akers Bio's flagship test for heparin-induced thrombocytopenia. Tony will lead the channel management strategy for Akers Bio in the US as we develop highly engaged, integrated business plans with our customers and distribution partners that enhance mutual gains in efficiency, productivity and profitability," he said.

Shares in Akers surged 7.7% to 105p on news of the announcements.

View full AKR profile View Profile

Akers Biosciences, Inc. Timeline

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use